



NGM Bio to Present at the Stifel 2019 Healthcare Conference

November 14, 2019

SOUTH SAN FRANCISCO, Calif., Nov. 14, 2019 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (Nasdaq: NGM), a clinical stage biotechnology company focused on developing transformative therapeutics for patients, today announced that David J. Woodhouse, Ph.D., Chief Executive Officer, will present at the Stifel 2019 Healthcare Conference in New York, NY on Tuesday, November 19, 2019 at 3:00 p.m. ET.

A live webcast of the presentation will be available under the Investors and Media section of NGM's website at <https://ir.ngmbio.com/events-presentations>. A replay of the presentation will be archived on NGM's site for 30 days following the event.

About NGM Biopharmaceuticals, Inc.

NGM is a clinical stage biopharmaceutical company focused on developing novel therapeutics based on scientific understanding of key biological pathways underlying cardio-metabolic, liver, oncologic and ophthalmic diseases. The company leverages its biology-centric drug discovery approach to uncover novel mechanisms of action and generate proprietary insights that enable it to move rapidly into proof-of-concept studies and deliver potential first-in-class medicines to patients. NGM aspires to operate one of the most productive research and development engines in the biopharmaceutical industry, with multiple programs in clinical development. Visit <http://www.ngmbio.com> for more information.

Investor Contact:

Sylvia Wheeler and Alex Santos
swheeler@wheelhousesa.com
asantos@wheelhousesa.com
ir@ngmbio.com

Media Contact:

Liz Melone
media@ngmbio.com